You are currently viewing German Curevac vaccine fails to achieve only 47% efficacy against covid-19 in definitive trial

The German company CureVac has made public this Wednesday the results of its Covid-19 vaccine, which has shown be only 47% effective in the definitive trial, which calls into question the delivery of more than 400 million doses committed to the European Union.

Efficacy has been rated as disappointing after learning that at least 134 cases of covid were registered in a study with about 40,000 volunteers.

CureVac it was on track to be the fifth vaccine authorized by the European Medicines Agency (EMA), and interest in her had escalated after what Janssen could not produce sufficient doses and the controversy over thrombotic events of Astrazeneca, rare but life threatening.

Messenger RNA technology, like Pfizer or Moderna, it was the great hope of developing countries because it only required a conventional fridge to be stored. According to Reuters, CureVac’s listed shares in the US fell 50.6% to $ 46.81 on Wednesday in after-hours trading after the data was released.


Disclaimer: If you need to update/edit/remove this news or article then please contact our support team Learn more